GlassScriptPhysician profile
Cheryl Lyon
NPI 1306262415
$11,597.54
in general payments reported to CMS, 2019-2025
33 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,732 · 2022: $2,720 · 2023: $1,750 · 2024: $2,501 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,145.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,430.49 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,066.40 | 2021-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $744.07 | 2021-2025 | Emgality, Reyvow, Zepbound |
| Amgen INC. | $735.93 | 2021-2024 | Aimovig |
| Scilex Pharmaceuticals INC. | $699.33 | 2023-2025 | Elyxyb |
| Lundbeck LLC | $566.52 | 2021-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $551.69 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $483.89 | 2021 | |
| Pfizer INC. | $464.14 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $417.94 | 2021-2024 | Onzetra Xsail, Contrave |
| Tonix Medicines, INC. | $410.23 | 2024-2025 | Zembrace Symtouch |
| Biohaven Pharmaceutical Holding Company LTD. | $381.92 | 2022 | |
| Ucb, INC. | $234.42 | 2021-2025 | Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $200.20 | 2021 | |
| Upsher-Smith Laboratories LLC | $187.25 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $98.33 | 2021-2022 | |
| Impel Pharmaceuticals LLC | $96.31 | 2024 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $91.94 | 2021-2022 | |
| Nevro Corp. | $84.91 | 2022 | |
| Arbor Pharmaceuticals, INC. | $79.31 | 2021 | |
| Supernus Pharmaceuticals, INC. | $75.05 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $74.61 | 2023 | Eprontia, Horizant |
| Novo Nordisk INC | $67.59 | 2024-2025 | Wegovy |
| Novocure INC. | $63.49 | 2021-2023 | Optune |
| Ibsa Pharma INC. | $50.51 | 2024 | Tirosint, Licart, Flector |
| Ge Healthcare | $49.11 | 2021-2023 | |
| Averitas Pharma INC. | $43.54 | 2024-2025 | Qutenza |
| Sk Life Science, INC. | $38.98 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $35.97 | 2021 | |
| Eisai INC. | $22.61 | 2024 | |
| Amneal Pharmaceuticals LLC | $21.20 | 2024 | Avastin |
| Collegium Pharmaceutical, INC. | $14.91 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.75 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Lyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.